(RTTNews) - iTeos Therapeutics (ITOS) has entered into a definitive merger agreement whereby Concentra Biosciences, LLC will acquire iTeos for $10.047 in cash per share of iTeos common stock par value $0.001 per share, plus one non-transferable contingent value right, which represents the right to receive: 100% of the closing net cash of iTeos in excess of $475 million; and 80% of any net proceeds received from any disposition of certain of iTeos product candidates that occurs within six months following the closing.
Concentra will commence a tender offer by August 1, 2025, to acquire all outstanding shares of iTeos common stock for the offer consideration.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
